Alnylam Posts 0.01% Rise with $560M Volume Ranking 176th as Executives Sell Shares Analysts Boost Ratings

On August 20, 2025, Alnylam Pharmaceuticals (NASDAQ:ALNY) closed with a 0.01% gain, trading on a volume of $560 million, ranking 176th in total trading activity. The biotech firm's recent performance drew attention amid executive stock transactions and updated analyst ratings.

Executive Vice President and Chief R&D Officer Pushkal Garg executed two stock sales totaling $1.3 million between August 18-19, 2025. The transactions, conducted under a pre-arranged Rule 10b5-1(c) plan, involved 1,143 shares at prices ranging from $447.98 to $455.82 on August 18, followed by 1,455 shares priced between $455.41 and $461.74 the next day. Garg's holdings remain substantial, including direct ownership of 20,221 shares and indirect holdings via managed accounts and trusts.

Analyst sentiment has shifted positively following Q2 results. The company reported adjusted earnings of $0.32 per share, surpassing the $-0.59 consensus estimate, with revenue rising to $773.7 million—$130.5 million above expectations. AMVUTTRA's performance in ATTR cardiomyopathy drove a 64% year-over-year increase in net product revenues to $672.2 million. Oppenheimer upgraded the stock to Outperform, citing Amvuttra's $150 million first-quarter sales, while Wolfe Research raised its rating to Peerperform and Truist maintained a Buy rating with a $459 price target ahead of zilebesiran KARDIA3 data presentation.

A strategy of purchasing the top 500 stocks by daily trading volume and holding for one day from 2022 to 2025 yielded a 1-day return of 0.98% and a cumulative 31.52% over 365 days, reflecting modest momentum capture amid market volatility and timing risks.